Article Text

PDF
CATT: Into the eye of a tiger
  1. Jonathan Sears1,2,
  2. James Bena3,
  3. Arun D Singh1
  1. 1Department of Ophthalmology, Cole Eye Institute, Cleveland, Ohio, USA
  2. 2Department of Cell Biology, Cleveland, Ohio, USA
  3. 3Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA
  1. Correspondence to Jonathan Sears, Cole Eye Institute Cleveland Clinic, Cleveland, Ohio, USA; searsj{at}ccf.org

Statistics from Altmetric.com

The anti-vascular endothelial growth factor (anti-VEGF) treatment of exudative age-related macular degeneration (AMD) provides an outstanding example of how the fruits of basic science research have been harvested to reduce blindness. After the initial discovery of VEGF,1 speculation that inhibiting the action of this protein alone might halt pathologic angiogenesis led to the development of neutralising anti-VEGF antibodies for use in understanding animal models of neovascularisation and as an adjunctive treatment for cancer.2 The next rational step was to design an ocular drug that was active against the VEGF epitope but was also otherwise inert to avoid interaction with the immune system. The former was developed as bevacizumab and the latter as ranubizumab.

It was then that clinicians returned a favour to basic scientists who discovered VEGF and its pathways, in two big surprises. First, it was amazing that blocking the action of a single protein induced such a dramatic inhibition, and regression, of choroidal neovascularisation, which depends on a complex cascade of inter and intra-molecular factors, proven in the ANCHOR and MARINA trials.3 4 Second, after understanding …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.